Issues in using progression-free survival when evaluating oncology products.

  title={Issues in using progression-free survival when evaluating oncology products.},
  author={Thomas R. Fleming and Mark D. Rothmann and Hong Laura Lu},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={27 17},
Several challenging and often controversial issues arise in oncology trials with the use of the end point progression-free survival (PFS), defined to be the time to detection of progressive disease or death. While this end point does not directly measure how a patient feels, functions, or survives, it does provide insights about whether an intervention affects the tumor burden process, the intended mechanism through which it is hoped that most anticancer agents will provide benefit. However… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.
65 Citations
0 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 65 extracted citations

Similar Papers

Loading similar papers…